9-ING-41
CAS No. 1034895-42-5
9-ING-41( —— )
Catalog No. M22563 CAS No. 1034895-42-5
9-ING-41 is a glycogen synthase kinase-3 inhibitor.9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 58 | In Stock |
|
| 5MG | 91 | In Stock |
|
| 10MG | 149 | In Stock |
|
| 25MG | 309 | In Stock |
|
| 50MG | 447 | In Stock |
|
| 100MG | 668 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name9-ING-41
-
NoteResearch use only, not for human use.
-
Brief Description9-ING-41 is a glycogen synthase kinase-3 inhibitor.9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM.
-
Description9-ING-41 is a glycogen synthase kinase-3 inhibitor.9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM. 9-ING-41 (1, 2 μM; 24 hours) is a potent cell cycle-blocking agent for lymphoma cells[2].9-ING-41 (40 mg/kg/every other day; for 17 days) has single-agent antitumor activity in a mouse model of MCL.
-
In VitroCell Viability Assay Cell Line:TCL and MCL lines Concentration:2, 4 μM Incubation Time:48 hours Result:Induced apoptosis.Cell Cycle Analysis Cell Line:Lymphoma cells (Jeko, Mino, and OCI-Ly cell lines) Concentration:1, 2 μM Incubation Time:24 hours Result:Led to cell cycle arrest in G2/M.Cell Autophagy Assay Cell Line:T24 cancer cells Concentration:25?μM Incubation Time:24?hours Result:Showed extensive vacuolation and formation of autophagosome like structures in the cytoplasm.Showed an increased expression of LC3, an autophagy marker.Western Blot Analysis Cell Line:SK-N-DZ and SK-N-BE neuroblastoma cells Concentration:0.1, 1 μM Incubation Time:48 hours Result:Inhibited GSK-3 leading to a decreased expression of the NF-κB target XIAP.
-
In VivoAnimal Model:NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice Dosage:40 mg/kg Administration:Every other day; for 17 days Result:Had single-agent antitumor activity in a mouse model of MCL.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3β
-
Research AreaOthers
-
IndicationMyelofibrosis
Chemical Information
-
CAS Number1034895-42-5
-
Formula Weight404.35
-
Molecular FormulaC22H13FN2O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:97 mg/mL (239.89mM; Need ultrasonic)
-
SMILESCn1cc(C2=C(C(=O)NC2=O)c2coc3ccc(F)cc23)c2cc3OCOc3cc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724.
molnova catalog
related products
-
GSK3β-IN-1a
GSK3β-IN-1a is a relatively selective and potent GSK-3β inhibitor with IC50 of 64 nM.
-
BRD1652
BRD1652 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 0.4 nM/4 nM for GSK3α/GSK3β respectively.
-
GSK3β inhibitor II
GSK3β inhibitor II is a GSK3β inhibitor. GSK3β inhibitor II exhibits the research potential of Alzheimer's disease (AD).
Cart
sales@molnova.com